Imagion Biosystems Limited
IBXXF
$0.01
-$0.02-66.67%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -82.00% | -65.56% | -46.15% | 0.93% | 64.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.00% | -65.56% | -46.15% | 0.93% | 64.95% |
| Cost of Revenue | -80.39% | -87.78% | -92.41% | -60.15% | -19.16% |
| Gross Profit | -84.15% | 20.65% | 788.34% | 619.76% | 536.69% |
| SG&A Expenses | -81.00% | -77.19% | -74.74% | -52.02% | -27.99% |
| Depreciation & Amortization | -98.77% | -81.32% | -67.16% | -42.64% | -18.73% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -82.36% | -80.76% | -79.74% | -53.72% | -24.81% |
| Operating Income | 82.74% | 90.31% | 93.72% | 73.62% | 52.76% |
| Income Before Tax | 65.89% | 77.71% | 83.63% | 66.05% | 47.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.89% | 77.71% | 83.63% | 66.05% | 47.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.89% | 77.71% | 83.63% | 66.05% | 47.70% |
| EBIT | 82.74% | 90.31% | 93.72% | 73.62% | 52.76% |
| EBITDA | 80.95% | 92.63% | 97.41% | 78.36% | 58.60% |
| EPS Basic | 90.90% | 87.96% | 86.72% | 70.77% | 55.07% |
| Normalized Basic EPS | 90.89% | 88.03% | 86.78% | 70.82% | 55.09% |
| EPS Diluted | 90.82% | 87.96% | 86.72% | 70.77% | 55.07% |
| Normalized Diluted EPS | 90.89% | 88.03% | 86.78% | 70.82% | 55.09% |
| Average Basic Shares Outstanding | 295.63% | 175.88% | 47.49% | 32.68% | 16.57% |
| Average Diluted Shares Outstanding | 295.63% | 175.88% | 47.49% | 32.68% | 16.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |